REDWOOD CITY, California, Jan. 7, 2014 /PRNewswire/ -- Denny Lanfear, President and CEO of Coherus Biosciences, will present at the J.P. Morgan 32nd Annual Healthcare Conference on Wednesday, January 15 at the Westin St. Francis in San Francisco, CA., beginning at 4:30pm Pacific Standard Time.
"Coherus' upcoming presentation at the conference marks an important milestone for our Company. This event will introduce Coherus Biosciences to a worldwide healthcare investor audience and reflects the good progress the Company has made with products and partnerships," stated Mr. Lanfear. "To date, Coherus has filed INDs on three products and completed partnership agreements in Asia, Latin America and Europe with major biopharma firms while retaining US rights on all its products. We believe that this progress distinguishes Coherus as the leading independent pure play biosimilar company."
About Coherus Biosciences
Founded in 2010, Coherus Biosciences is a leading pure play biosimilar platform Company headquartered in the San Francisco Bay Area. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases. Our vision is to increase global patient access to high quality, life changing biologic medications. Coherus' global partnerships include top tier BioPharma companies in Europe, Asia, and Latin America who are pursuing the integrated development and commercialization of products representing over $35 billion in current global sales. From conceptualization to commercialization, Coherus' unique business model leverages a strategic consortium of key service providers aligned through ownership and shared incentives. Through these partnerships, the Company has built a capital efficient infrastructure capable of taking products from cell lines to approved labels. To date, Coherus has raised approximately $125 million from equity and non-dilutive licensing fees. Existing investors include KMG Capital, Lilly Ventures, Sofinnova and Venrock.
Coherus Biosciences Contact
SOURCE Coherus BioSciences